NCT05797610进行中（未招募）3 期
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 459
- 试验地点
- 454
- 主要终点
- Change From Baseline in the Urine Protein-to-Creatinine Ratio (UPCR) at Week 37
研究概览
简要总结
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primary IgAN, as evidenced by a kidney biopsy performed within 10 years prior to or during screening, without known secondary cause
- •Treatment with maximum tolerated doses of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for at least 90 days immediately prior to screening, and without an intent to modify the dose during the study, except for interruptions due to illness (not greater than 7 consecutive days), unless the potential participant is intolerant to these medications
- •Urine Protein-to-Creatinine Ratio (UPCR) ≥ 1 gram per gram (g/g) or urine protein excretion ≥ 1 gram per day (g/day) (with UPCR ≥ 0.8 g/g), all measured from a 24-hour urine collection during screening
- •eGFR ≥ 20 mL/min/1.73 m^2, as calculated by the 2021 CKD-EPI creatinine equation (Inker et al. 2021a)
- •Vaccination against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae according to national vaccination recommendations
- •Female participants of childbearing potential must use adequate contraception
排除标准
- •Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 12 weeks after the final dose of sefaxersen
- •Histopathologic or other evidence of another autoimmune glomerular disease
- •Presence of ≥ 50% crescents on kidney biopsy, sustained doubling of serum creatinine within 3 months prior to screening, or rapidly progressive glomerulonephritis in the opinion of the investigator
- •History of kidney transplantation
- •Glycated Hemoglobin (HbA1c) ≥ 6.5% or a clinical diagnosis of diabetes mellitus of any type
- •Systolic blood pressure >140 millimetre of mercury (mmHg) or diastolic blood pressure >90 mmHg from the average of two measurements performed at least 1 minute apart during screening
- •Initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors within 16 weeks prior to screening or during screening
- •Initiation of endothelin receptor antagonists within 90 days prior to screening or during screening
- •Initiation of mineralocorticoid receptor antagonists or non-dihydropyridine calcium channel blockers within 90 days prior to screening or during screening
- •Use of herbal therapies within 90 days prior to or during screening
- •Treatment with investigational therapy within 28 days prior to screening or 5.5 drug-elimination half-lives of that investigational product prior to screening
- •Treatment with an investigational therapy planned during the treatment period
- •Previous treatment with sefaxersen
- •Treatment with oral or intravenous (IV) corticosteroids with a dose equivalent to ≥ 7.5 milligrams per day (mg/day) of prednisone for 7 days or equivalent to ≥ 5 mg/day of prednisone for 14 days within 90 days prior to screening
- •Treatment with corticosteroids with systemic effects during screening
- •Treatment with a systemic calcineurin inhibitor within 2 months prior to screening or during screening
- •Treatment with anti-CD20 therapy within 9 months of screening or during screening
- •Treatment with other systemic immunosuppressive agents within 6 months of randomization including, but not limited to, complement inhibitors, alkylating agents (e.g., cyclophosphamide or chlorambucil), azathioprine, or mycophenolate
- •Planned major procedure or major surgery during screening or the study
- •Substance abuse within 12 months prior to screening or during screening
- •Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study
- •History of malignancy within < 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
- •Usage of Glucagon-like Peptide-1 (GLP-1)-based therapy (i.e., GLP-1 mono-agonists, GLP-1/GIP dual agonists, etc.) within 90 days prior to screening or during screening, or intent to initiate during the study period
研究组 & 干预措施
Sefaxersen (RO7434656)
Experimental
Participants will receive subcutaneous (SC) doses of sefaxersen (RO7434656) on Days 1, 15, and 29 followed by once every 4 weeks (Q4W) until Week 105. Participants may be eligible to switch to open-label treatment after Week 105 at the investigator's discretion or after the common-close timepoint, whichever occurs first. The common-close timepoint is defined as the data cut-off date for the primary analysis, when approximately 230 participants in the primary cohort have completed the Week 105 visit.
干预措施: Sefaxersen (RO7434656) (Drug)
Placebo
Placebo Comparator
Participants will receive SC doses of sefaxersen (RO7434656) matching placebo on Days 1, 15, and 29 followed by once Q4W until Week 105. Participants may be eligible to switch to open-label treatment after Week 105 at the investigator's discretion or after the common-close timepoint, whichever occurs first. The common-close timepoint is defined as the data cut-off date for the primary analysis, when approximately 230 participants in the primary cohort have completed the Week 105 visit.
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in the Urine Protein-to-Creatinine Ratio (UPCR) at Week 37
时间窗: Baseline, Week 37
UPCR will be assessed in urine sampled over 24 hours.
次要结局
- Estimated Glomerular Filtration Rate (eGFR) Slope at Week 105 from Baseline(Baseline, Week 105)
- Change From Baseline in Fatigue at Week 105(Baseline, Week 105)
- Estimated Glomerular Filtration Rate (eGFR) Slope at Week 105 from Baseline(Baseline, Week 105)
- Change From Baseline in Fatigue at Week 105(Baseline, Week 105)
- Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs)(Up to approximately 36 months)
- Plasma Concentration of Sefaxersen(Up to approximately 36 months)
- Time to the Composite Kidney Failure Endpoint(Up to approximately 36 months)
- Percentage of Participants Achieving Hematuria Resolution at Week 37(At Week 37)
研究者
研究点 (454)
Loading locations...
相似试验
已完成
2 期
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)Autism Spectrum Disorder (ASD)NCT04299464Hoffmann-La Roche104
已完成
2 期
A Dose-Finding Study of RO4998452 in Patients With Diabetes MellitusDiabetes Mellitus Type 2NCT00800176Hoffmann-La Roche394
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic SclerosisSystemic SclerosisNCT05462522Genentech, Inc.56
撤回
3 期
A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial PneumoniaHospital-Acquired Bacterial PneumoniaVentilator-Associated Bacterial PneumoniaHospital-Acquired PneumoniaVentilator-Associated PneumoniaNCT03006679Melinta Therapeutics, Inc.
已完成
2 期
Study of the Effect of SR57667B in Patients With Alzheimer's DiseaseAlzheimer DiseaseNCT00285025Sanofi500